TRAVERE THERAPEUTICS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$491M
Cost of Revenue
$10M
R&D
$206M
SG&A
$337M
D&A
$61M
Operating Income
$-63M
EBITDA
$-2M
Interest Expense
$11M
Interest Income
$13M
Other Income/Expense
$12M
Pretax Income
$-49M
Tax Provision
$988K
Net Income
$-26M
Operating Margin
-12.8%
Net Margin
-5.2%
Effective Tax Rate
-2.0%
Revenue YoY Variation
110.5%
Income YoY Variation
80.6%